Compare LPL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | IOVA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.7B |
| IPO Year | 2004 | 2008 |
| Metric | LPL | IOVA |
|---|---|---|
| Price | $2.98 | $10.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 2.0M | ★ 13.0M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | $47.74 |
| Revenue Next Year | $2.94 | $40.31 |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $1.76 |
| 52 Week High | $5.83 | $9.36 |
| Indicator | LPL | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 70.70 |
| Support Level | $2.76 | $3.82 |
| Resistance Level | $3.43 | N/A |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 22.68 | 86.11 |
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.